	US 12,286,639 B2
	LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof
Thomas Schaser, Rösrath (DE); Johann-Christoph Dettmann, Bergisch Gladbach (DE); Martin Meyer, Kürten (DE); and Ian Johnston, Rösrath (DE)
Assigned to MILTENYI BIOTEC B.V. & CO. KG, Bergisch Gladbach (DE)
Appl. No. 17/264,763
Filed by Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach (DE)
PCT Filed Aug. 28, 2019, PCT No. PCT/EP2019/072931 § 371(c)(1), (2) Date Jan. 29, 2021, PCT Pub. No. WO2020/043765, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 18191784 (EP), filed on Aug. 30, 2018.
Prior Publication US 2021/0301307 A1, Sep. 30, 2021
Int. Cl. C12N 15/86 (2006.01); C12N 7/00 (2006.01)

CPC C12N 15/86 (2013.01) [C12N 7/00 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2810/6081 (2013.01)]

24 Claims

1. A method for producing vesicular stomatitis virus envelope protein (VSV-G) pseudotyped vectors that contain a Ψ-positive nucleic acid encoding one or more transgene products or virus-like particles thereof containing said transgene product(s),

the method comprising:

obtaining cells from a packaging cell line that has been stably adapted and/or selected to not express cell surface low density lipoprotein receptor (LDLR);

causing the cells to express VSV-G, gag/pol, and optionally rev; and

causing the cells to express said Ψ-positive nucleic acid or said transgene product(s), whereby the cells produce said pseudotyped vectors or virus-like particles; then

harvesting from the cells said pseudotyped vectors or virus-like particles.